Scholarlink

Background <p>Allergic rhinitis (AR) is highly prevalent in Asia, but limited data exist on the real-world effectiveness of MP-AzeFlu (azelastine/fluticasone combination nasal spray) in Asian populations.</p> Objective <p>To evaluate the real-world effectiveness of MP-AzeFlu in Asian patients with moderate-to-severe AR.</p> Methods <p>This prospective, multicenter, noninterventional study enrolled patients with moderate-to-severe AR in Thailand, Taiwan, Malaysia, and Hong Kong. The patients received MP-AzeFlu and completed visual analog scale (VAS) assessments for AR symptoms over 28 days. The primary outcome was the proportion of responders (VAS score &lt; 50 mm at least once during follow-up).</p> Results <p>Of the 916 patients included in the safety population, 329 (35.92%) were males and 587 (64.08%) were females. Significant improvements were observed in the overall AR and nasal and ocular symptoms from day 1 through day 28 (<i>p</i> &lt; 0.0001 for all). Asthma symptoms improved significantly in patients with comorbid asthma (11.7%), and 60% reduced use of asthma reliever medication was reported. Quality of life measures, including sleep quality and daily activities, also improved significantly. MP-AzeFlu was well-tolerated, with only six patients reporting mild adverse events.</p> Conclusions <p>In this real-world study, MP-AzeFlu provided rapid and sustained improvement in AR symptoms and quality of life in Asian patients with moderate-to-severe AR. MP-AzeFlu has also shown beneficial effects in patients with comorbid asthma. These results support the effectiveness of MP-AzeFlu in AR management in Asian populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu in Asian Patients with Allergic Rhinitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Pongsakorn Tantilipikorn,
  • Yau Kay Chung Julian,
  • Te-Huei Yeh,
  • Yap Yoke Yeow,
  • George Chow,
  • Hans Christian Kuhl,
  • Duc Tung Nguyen,
  • Rajesh Kumar Ramalingam

摘要

Background

Allergic rhinitis (AR) is highly prevalent in Asia, but limited data exist on the real-world effectiveness of MP-AzeFlu (azelastine/fluticasone combination nasal spray) in Asian populations.

Objective

To evaluate the real-world effectiveness of MP-AzeFlu in Asian patients with moderate-to-severe AR.

Methods

This prospective, multicenter, noninterventional study enrolled patients with moderate-to-severe AR in Thailand, Taiwan, Malaysia, and Hong Kong. The patients received MP-AzeFlu and completed visual analog scale (VAS) assessments for AR symptoms over 28 days. The primary outcome was the proportion of responders (VAS score < 50 mm at least once during follow-up).

Results

Of the 916 patients included in the safety population, 329 (35.92%) were males and 587 (64.08%) were females. Significant improvements were observed in the overall AR and nasal and ocular symptoms from day 1 through day 28 (p < 0.0001 for all). Asthma symptoms improved significantly in patients with comorbid asthma (11.7%), and 60% reduced use of asthma reliever medication was reported. Quality of life measures, including sleep quality and daily activities, also improved significantly. MP-AzeFlu was well-tolerated, with only six patients reporting mild adverse events.

Conclusions

In this real-world study, MP-AzeFlu provided rapid and sustained improvement in AR symptoms and quality of life in Asian patients with moderate-to-severe AR. MP-AzeFlu has also shown beneficial effects in patients with comorbid asthma. These results support the effectiveness of MP-AzeFlu in AR management in Asian populations.